


Suppl. figure e-1

A



B




Figure e-1 Sustained NEDA outcomes for 4 years in patients who received only the initial 2 courses of alemtuzumab

(A) Schematic for the methodology for describing patients with 4-year sustained NEDA. (B) NEDA outcomes were assessed for patients who received the initial 2 alemtuzumab courses in the core CARE-MS II study, achieved NEDA at Year 2 of the core study, and received no alemtuzumab retreatment since Month 12 or treatment with another DMT through 5 years. Sustained outcomes were calculated cumulatively over Years 2–5. ^aBaseline percentage of patients Gd-enhancing lesion-free: 59%. CDW = confirmed disability worsening; DMT = disease-modifying therapy; Gd = gadolinium; NEDA = no evidence of disease activity.